Aligos Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
ALGS$2.57-34.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated State ments of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(24,193) | $(131,211) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Accretion of discount on investments | (2,188) | (1,783) |
| Non cash lease expense | 1,875 | 1,595 |
| Change in fair value of 2023 Common Warrants | (60,184) | 46,132 |
| Depreciation expense | 930 | 1,027 |
| Stock-based compensation including ESPP | 5,044 | 8,452 |
| Changes in operating assets and liabilities: | ||
| Accounts payable | 1,411 | 54 |
| Accrued liabilities | (2,031) | (1,388) |
| Operating lease liabilities | (3,112) | (2,680) |
| Deferred revenue | (151) | (1,157) |
| Other assets | 96 | 216 |
| Net cash and cash equivalents used in operating activities | (82,503) | (80,743) |
| Cash flows from investing activities: | ||
| Maturities of short-term investments | 127,500 | 90,000 |
| Purchase of short-term investments | (164,889) | (108,149) |
| Purchases of property and equipment | (437) | (130) |
| Net cash and cash equivalents used in investing activities | (37,826) | (18,279) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock upon exercise of pre-funded warrants | - | 2 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants in connection with PIPE offering, net of costs | 101,345 | - |
| Payments on finance lease | (14) | (83) |
| Proceeds from the ESPP purchase | 304 | 436 |
| Net cash and cash equivalents provided by financing activities | 101,635 | 355 |
| Net decrease in cash, cash equivalents, and restricted cash | (18,694) | (98,667) |
| Cash, cash equivalents, and restricted cash, beginning of period | 37,107 | 135,774 |
| Cash, cash equivalents, and restricted cash, end of period | $18,413 | $37,107 |
Aligos Therapeutics, Inc.
Notes to consolidated
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.